Skip to main content
Indian stocks: Visit www.stage2stocks.com →

Amphastar Pharmaceuticals, Inc.

Stage 2 · Advancing · week 3

As of Oct 22, 2026, Amphastar Pharmaceuticals is in Stage 2, the uptrend phase, now in week 3 (since Oct 2, 2026). It closed at $26.04, 11.4% below its 52-week high and above its 200-day average, which is falling.

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. More about the company

$26.04
-0.61% today
$1.1B · Small cap
Market Neutral — Building

Pro read

Pro

Our read

Early entry: still early enough in its move

Setup score

—

Momentum

Steady

Edge

—

Setup-score rank among Stage 2 peers: #1 of 26 in Drug Manufacturers - Specialty & Generic · #1 of 272 in Health Care

Is AMPH early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S4 23w
S4 32w
S4 21w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S2 4w → S3 11w → S2 12w → S3 3w → S4 23w → S1 7w → S2 7w → S3 6w → S4 32w → S1 8w → S2 2w → S3 1w → S4 7w → S2 10w → S3 1w → S4 21w → S1 7w → S2 3w current
Total tracked: 165 weeks across 18 stage runs.

AMPH among Drug Manufacturers - Specialty & Generic26th of 84 by relative strength

All 84 →
Stocks in Drug Manufacturers - Specialty & Generic ranked by relative strength, with stage and one-month change
#StockStageRS1M
1CPIXStage 2 · wk 2398+6.8%
2ETONStage 2 · wk 3097−10.1%
3ANIKStage 2 · wk 1596+3.5%
4IRWDStage 3 · wk 396−16.4%
5TEVAStage 2 · wk 995+3.1%
6AMRXStage 2 · wk 1995+5.9%
7KNSAStage 2 · wk 7395+6.2%
8AMLXStage 2 · wk 1593−6.6%
…26AMPHStage 2 · wk 360+4.3%
vs 52W High
-11.4%
$16.87 lo$29.40 hi
11.4% below 52W high, pullback range
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 3
1w13w26w
Week 3, fresh breakout
How long this stock has been in Stage 2. The sweet spot is mid-run: long enough to prove the structure holds, not so long that it's extended. Very fresh moves (weeks 1–4) often need more time to confirm.
vs 200 DMA
16.7%
200 DMA: $22.31 · sloping down
Long-term trend anchor. When the stock and the S&P 500 are both above their 200-day averages, the backdrop supports continuation.
Rel Volume
0.69x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
↑
Short-term trend rising strongly
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
+4.3%
3M
+39.1%
6M
+23.9%
YTD
-1.6%
1Y
+7.3%
Scan Membership
Breakout Watch
Latest: 2024-10-09
8 appearances in last 60 days. First seen: 2018-10-16.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S2
Wk 3 · Vol 0.69x
2026-10-21S2
Wk 3 · Vol 0.65x
2026-10-20S2
Wk 3 · Vol 0.78x
2026-10-19S2
Wk 3 · Vol 0.62x
2026-10-16S2
Wk 3 · Vol 0.72x
2026-10-15S2
Wk 2 · Vol 0.72x
2026-10-14S2
Wk 2 · Vol 0.74x
2026-10-13S2
Wk 2 · Vol 0.66x
2026-10-12S2
Wk 2 · Vol 0.74x
2026-10-09S2
Wk 2 · Vol 0.89x
2026-10-08S2
Wk 1 · Vol 0.87x
2026-10-07S2
Wk 1 · Vol 1.62x
Moving averages & range
50 DMA
$24.16
200 DMA
$22.31
52W High
$29.40
52W Low
$16.87
5D Low
$25.87
Resistance levels (recent highs)
20d High
$27.39
60d High
$27.39
120d High
$27.39
250d High
$29.40
Next resistance
+5.2%
to 20d High
P/E (TTM)
15.4
Forward 8.2
Earnings Growth (YoY)
+4.7%
Revenue +5.4%
ROE
+10.3%
Profit margin +10.8%
Dividend Yield
0.00%
P/B 1.4

Amphastar Pharmaceuticals: quick answers

What stage is Amphastar Pharmaceuticals in?

As of Oct 22, 2026, Amphastar Pharmaceuticals (AMPH) is in Stage 2, the uptrend phase. It entered Stage 2 on Oct 2, 2026 and is in week 3. What the four stages mean

Is Amphastar Pharmaceuticals in an uptrend?

Yes. Amphastar Pharmaceuticals is in a Stage 2 uptrend. It trades 16.7% above its 200-day average, which is falling.

How far is Amphastar Pharmaceuticals from its 52-week high?

Amphastar Pharmaceuticals closed at $26.04 on Oct 22, 2026, 11.4% below its 52-week high of $29.40. Its 52-week low is $16.87.

How has Amphastar Pharmaceuticals performed over the past year?

As of Oct 22, 2026, Amphastar Pharmaceuticals is up 7.3% over the past year and down 1.6% so far in 2026.

Which sector and industry is Amphastar Pharmaceuticals in?

Amphastar Pharmaceuticals is in the Drug Manufacturers - Specialty & Generic industry, part of the Health Care sector.

About this companyHealth Care· Drug Manufacturers - Specialty & Generic

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Glucagon for injection emergency kit; Enoxaparin, an injectable form of low molecular weight heparin for the prevention and treatment of deep vein thrombosis; and REXTOVY and Naloxone for opioid overdose. The company also provides Cortrosyn, a lyophilized power for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; and emergency syringe products, including atropine, calcium chloride, dextrose, epinephrine, lidocaine, and sodium bicarbonate. In addition, it offers Albuterol sulfate inhalation aerosol for the treatment or prevention of bronchospasm; Iron sucrose injection, an iron replacement product for the treatment of iron deficiency anemia in patients with chronic kidney disease; Teriparatide injection for managing daily osteoporosis therapy; and Ipratropium Bromide HFA inhalation aerosol, an anticholinergic indicated for the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease. Further, the company provides active pharmaceutical ingredient (API) products, such as Recombinant Human Insulin and porcine insulin API. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.